Did you know?

Aug 18, 2022 · SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse ... Find the latest Earnings Report Date for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com.Find the latest on option chains for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com.Find the latest Insider Activity data for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com. SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...View the latest Unity Biotechnology Inc. (UBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Find the latest news headlines from Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...Follow. SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...Home UBX • NASDAQ. Unity Biotechnology Inc. Follow. Share. $1.92. After Hours: $1.91. (0.52%) -0.0100. Closed: Dec 1, 7:36:27 PM GMT-5 · USD · NASDAQ · Disclaimer. SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing ...Real time Unity Biotechnology (UBX) stock price quote, stock graph, news & analysis. Find the latest on option chains for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com. Last November, Wedbush analyst Andreas Argyrides raised his price target on Unity Biotechnology, Inc. (NASDAQ:UBX) to $36 from $4 and maintained an Outperform rating on the shares.Overview Stock Screener Earnings Calendar Sectors Nasdaq | UBX U.S.: Nasdaq Unity Biotechnology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Oct 27, 2023 7:54 p.m....Unity Biotechnology upgraded to Outperform from Neutral at Wedbush November 16, 2023TipRanks. Unity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy ...Unity Biotechnology, Inc. (UBX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. View the basic UBX option chain and compare options of Unity Biotechnology, Inc. on Yahoo Finance.Aug 5, 2022 · Unity Biotechnology, Inc. (NASDAQ:UBX) shareholders should be happy to see the share price up 23% in the last month. But only the myopic could ignore the astounding decline over three years. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...Unity Biotechnology, Inc. (NASDAQ:UBX) was in 4 hedge funds’ portfolios at the end of September. UBX shareholders have witnessed a decrease in hedge fund interest recently. There were 5 hedge ...SOUTH SAN FRANCISCO, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...Feb 14, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ... Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate. Unity Biotechnology ( NASDAQ: UBX) lost ~48% pre-market Monday after announcing that its lead candidate UBX1325 failed to ...The average price point forecasted by analysts for Unity Unity Biotechnology Stock (NASDAQ:UBX), Analyst Ratings, P SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ... This has heavy trading pulling shares of SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing ...52-week range: $0.42 – $3.64 Unity Biotechnology (NASDAQ:UBX) focuses primarily on the development of therapeutics that target age-related ophthalmologic and neurologic diseases.. Its central ... November 1, at 8:00 a.m. ET. SOUTH SAN FRANCISCO,

SAN FRANCISCO, March 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or ...Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities researchers at Wedbush upped their FY2023 earnings per share estimates for shares of Unity Biotechnology in a research report issued to clients and investors on Thursday, November 16th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings per share of ($2.66) for the […]SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...Unity Biotechnology (NASDAQ: UBX) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development that Unity is ...

Find the latest Insider Activity data for Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com.Oct 17, 2023 · Unity Biotechnology (NASDAQ: UBX) primarily focuses on developing therapeutics targeting age-related ophthalmologic and neurologic diseases. Its main candidate, UBX1325, is being studied for ... …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Last November, Wedbush analyst Andreas Arg. Possible cause: As of March 2015, Theranos is a private company and does not have a public stock .